Success in the clinic with caplacizumab for aTTP and a big IPO in the USA has put the Belgium-headquartered group in the spotlight.
Fresh from its clinical success with caplacizumab, Ablynx NV has priced its initial US public offering totaling $200m, propelling the company's market capitalization over the €1bn mark.
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
GNT Pharma prepares for the first listing of a Korean biotech on Nasdaq, while others sign major global out-licensing deals with large multinational partners.
With the FDA asking for another Phase III trial, the short bowel syndrome drug apraglutide could be years away from market, while the Linzess patent expiry and near-term debt loom.
The company discontinued development of its oral GLP-1 receptor agonist for weight management due to a safety signal.
The Oxford group has linked up with the NHS Cancer Vaccine Launch Pad.
The bispecific is the first in its class to record a Phase III survival win in small-cell lung cancer, although antibody-drug conjugates and other rivals could challenge in the coming years.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
The Oxford group has linked up with the NHS Cancer Vaccine Launch Pad.
